Human Milk Oligosaccharide Array

10607

From: $994.00

The human milk oligosaccharide (HMO) glycan array allows researchers to explore the interactions between HMO and various biological samples, for example, proteins, antibodies, cells, cell lysate, serum, vesicles, bacteria, or viral particles. The HMO glycan array features 46 structurally – defined oligosaccharides prevalent in human breast milk. Each array slide contains 16 identical subarrays, enabling the simultaneous analysis of multiple samples. Results can be obtained in only a few hours, making investigating HMO binding easy and efficient. The HMO glycan array provides high-throughput and reliable HMO-binding information. It can be customized to meet individual client needs. Assay services are available upon request.

SKU: 10607 Category:
Description
Structures
Examples
Document

Description

Human milk oligosaccharides (HMOs) are the third most abundant component of human breast milk. They are a class of complex sugar molecules that positively influence infant development. For example, HMOs stimulate the growth of symbiotic bacteria in the gut, protect against infection and disease, and promote the healthy development of the infant’s gut, brain, and immune function. Many of these beneficial effects are associated with specific epitope structures of HMOs. HMOs have been used as biomarkers to evaluate infant digestive development, diarrhea incidence, morbidity and mortality, and risk of developing certain disorders. In addition to their vital roles in early infant development, HMOs have been found to inhibit pathogens and constrain tumor cell growth.

HMOs are structurally diverse, and more than one hundred structurally distinct HMOs have been identified to date. The composition and abundance of HMOs in breast milk vary from woman to woman over lactation. For example, modification by fucosylation is determined by the genetic background of the mother and whether specific fucosyltransferase genes (e.g., FUT2 or FUT3) are present as wild-type, mutated, or deleted. Fucosylation of the HMO backbone further impacts HMO bioactivity. The health benefits of HMOs are increasingly recognized, and enormous studies are underway to understand further their functions, binding partners, and the relationship between their structures and biological roles.

ZBiotech has developed a robust microarray platform that allows researchers to explore the interactions between HMO and various biological samples, for example, proteins, antibodies, cells, cell lysate, serum, vesicles, bacteria, or viral particles. The HMO glycan array features 46 structurally – defined oligosaccharides prevalent in human breast milk. Each array slide contains 16 identical subarrays, enabling the simultaneous analysis of multiple samples. Results can be obtained in only a few hours, making investigating HMO binding easy and efficient. The HMO glycan array provides high-throughput and reliable HMO-binding information. It can be customized to meet individual client needs. Assay services are available upon request.

Features

  • 46 structurally – defined HMO structures prevalent in human breast milk;
  • Unrivaled sensitivity and specificity;
  • Simple assay format;
  • Small sample volume;
  • Customizable (select HMOs for a specific microarray format)
  • Assay service available;

Applications

  • Evaluate binding specificities of HMO-interacting proteins;
  • Evaluate binding specificities of HMO-interacting antibodies;
  • Study virus – HMO interactions;
  • Study bacteria – HMO glycan interactions;
  • Study vesicle – HMO glycan interactions;
  • Study cell – HMO glycan interactions;

Structures

List of human milk oligosaccharide structures on the array (download the PDF)

ID Structure Common Name
HMO1 Galβ1-4Glc Lactose
HMO2 Galβ1-4(Fucα1-3)Glc 3-FL
HMO3 Fucα1-2Galβ1-4Glc 2′-FL
HMO4 Neu5Acα2-3Galβ1-4Glc 3′-SL
HMO5 Neu5Acα2-6Galβ1-4Glc 6′-SL
HMO6 Galα1-4Galβ1-4Glc Gb3 (Pk antigen)
HMO7 GalNAcβ1-3Galα1-4Galβ1-4Glc Gb4
HMO8 Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glc Gb5 (SSEA-3)
HMO9 Fucα1-2Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glc Globo-H
HMO10 Galβ1-3GlcNAcβ1-3Galβ1-4Glc LNT
HMO11 Galβ1-4GlcNAcβ1-3Galβ1-4Glc LNnT
HMO12 Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glc LNFP-I
HMO13 Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4Glc LNFP-II
HMO14 Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc LNFP-III
HMO15 Fucα1-2Galβ1-4GlcNAcβ1-3Galβ1-4Glc Blood group H antigen
HMO16 Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc LeY
HMO17 Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4Glc LsTc-I
HMO18 Galβ1-4GlcNAcβ1-3(Neu5Acα2-6)Galβ1-4Glc LsTc-II
HMO19 Neu5Acα2-3Galβ1-3GlcNAcβ1-3Galβ1-4Glc LsTa
HMO20 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4Glc Ac3-LNnT
HMO21 Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4Glc Ac6-LNnT
HMO22 Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GlcNAcβ1-3Galβ1-4Glc DSLNT
HMO23 GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glc Lacto-N-neoPentaose (LNnP)
HMO24 GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc Fuc-LNnP
HMO25 GlcNAcβ1-6(GlcNAcβ1-3)Galβ1-4Glc N/A
HMO26 GlcNAcβ1-6(Galβ1-4GlcNAcβ1-3)Galβ1-4Glc N/A
HMO27 GlcNAcβ1-6(Galβ1-3GlcNAcβ1-3)Galβ1-4Glc N/A
HMO28 GlcNAcβ1-6(Neu5Acα2-6Galβ1-4GlcNAcβ1-3)Galβ1-4Glc N/A
HMO29 GlcNAcβ1-6(Neu5Acα2-6Galβ1-3GlcNAcβ1-3)Galβ1-4Glc N/A
HMO30 GlcNAcβ1-6(Neu5Acα2-3Galβ1-3GlcNAcβ1-3)Galβ1-4Glc N/A
HMO31 GlcNAcβ1-6(Galβ1-4(Fucα1-3)GlcNAcβ1-3)Galβ1-4Glc N/A
HMO32 GlcNAcβ1-6(Fucα1-2Galβ1-4GlcNAcβ1-3)Galβ1-4Glc N/A
HMO33 GlcNAcβ1-6(Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ1-3)Galβ1-4Glc N/A
HMO34 Galβ1-4GlcNAcβ1-6(GlcNAcβ1-3)Galβ1-4Glc N/A
HMO35 Neu5Acα2-6Galβ1-4GlcNAcβ1-6(GlcNAcβ1-3)Galβ1-4Glc N/A
HMO36 Galβ1-4(Fucα1-3)GlcNAcβ1-6(GlcNAcβ1-3)Galβ1-4Glc N/A
HMO37 Fucα1-2Galβ1-4GlcNAcβ1-6(GlcNAcβ1-3)Galβ1-4Glc N/A
HMO38 Galβ1-4GlcNAcβ1-6(Neu5Acα2-6Galβ1-4GlcNAcβ1-3)Galβ1-4Glc N/A
HMO39 Galβ1-4GlcNAcβ1-6(Neu5Acα2-6Galβ1-3GlcNAcβ1-3)Galβ1-4Glc N/A
HMO40 Galβ1-4GlcNAcβ1-6(Fucα1-2Galβ1-4GlcNAcβ1-3)Galβ1-4Glc N/A
HMO41 Neu5Acα2-6Galβ1-4GlcNAcβ1-6(Galβ1-4GlcNAcβ1-3)Galβ1-4Glc N/A
HMO42 Neu5Gcα2-6Galβ1-4GlcNAcβ1-6(Galβ1-4GlcNAcβ1-3)Galβ1-4Glc N/A
HMO43 Galβ1-4(Fucα1-3)GlcNAcβ1-6(Galβ1-4GlcNAcβ1-3)Galβ1-4Glc N/A
HMO44 Neu5Gcα2-6Galβ1-4GlcNAcβ1-6(Neu5Gcα2-6Galβ1-4GlcNAcβ1-3)Galβ1-4Glc N/A
HMO45 Fucα1-2Galβ1-4GlcNAcβ1-6(Fucα1-2Galβ1-4GlcNAcβ1-3)Galβ1-4Glc N/A
HMO46 Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ1-6(Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ1-3)Galβ1-4Glc N/A

Examples

Aleuria Aurantia Lectin (AAL) binds to multiple human milk oligosaccharides

The HMO glycan array was assayed with biotinylated AAL lectin (10 μg/ml), followed by streptavidin-Cy3 (1 μg/ml). The array was scanned with a microarray scanner at 532nm wavelength. Positive control showed binding signals as expected. AAL binds to multiple human milk oligosaccharides.

Document

List of human milk oligosaccharide structures on the array (download the PDF)

Protocol & User Manual (download the manual)